2026年阿布扎比试验将测试BioSapien的MediChip用改良化疗方法治疗低GI癌症。 A 2026 Abu Dhabi trial will test BioSapien’s MediChip for treating lower GI cancers with improved chemotherapy delivery.

在阿布扎比, 为期六个月的肿瘤临床试验将于2026年Q1开始, 将测试BioSapien的麦地契平台, 治疗低肠胃癌。 A six-month oncology clinical trial in Abu Dhabi, set to begin in Q1 2026, will test BioSapien’s MediChip platform for treating lower gastrointestinal cancers. 由IROS作为主要服务提供者牵头的这一试验旨在改进化疗的提供,减少系统性副作用,提高患者结果。 The trial, led by IROS as the primary service provider, aims to improve chemotherapy delivery, reduce systemic side effects, and enhance patient outcomes. 这一伙伴关系强调了阿布扎比在精密医学和全球临床研究方面日益扩大的作用,加强了阿联酋作为一个生物技术创新枢纽的崛起。 The partnership underscores Abu Dhabi’s expanding role in precision medicine and global clinical research, reinforcing the UAE’s emergence as a biotech innovation hub.